CD47 and glioblastoma: While anti-GBM responses of anti-CD47 are somewhat limited as a monotherapy26,27, integrating anti-CD47 mechanisms into a therapeutic platform that coordinately modulates multiple functionalities of TAMCs may prove beneficial.